home / stock / ntec / ntec quote
Last: | $9.63 |
---|---|
Change Percent: | -12.48% |
Open: | $11 |
Close: | $9.63 |
High: | $11.0973 |
Low: | $9.59 |
Volume: | 980,394 |
Last Trade Date Time: | 08/03/2021 04:42:34 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.63 | $11 | $9.63 | $11.0973 | $9.59 | 980,394 | 08-03-2021 |
$11.0031 | $11.16 | $11.0031 | $12.3 | $10.98 | 475,030 | 08-02-2021 |
$11.29 | $11.82 | $11.29 | $11.9516 | $10.6 | 1,528,254 | 07-30-2021 |
$13.55 | $10.05 | $13.55 | $17.8 | $9.92 | 34,139,607 | 07-29-2021 |
$9.15 | $8.98 | $9.15 | $9.63 | $8.8601 | 664,344 | 07-28-2021 |
$9.05 | $9.61 | $9.05 | $10.5973 | $8.88 | 609,560 | 07-27-2021 |
$2.57 | $2.82 | $2.57 | $2.83 | $2.55 | 1,969,270 | 07-26-2021 |
$3.41 | $3.62 | $3.41 | $3.65 | $3.3 | 1,678,245 | 07-23-2021 |
$3.71 | $3.58 | $3.71 | $4.3 | $3.52 | 7,343,634 | 07-22-2021 |
$3.62 | $3.36 | $3.62 | $3.8599 | $3.33 | 2,229,962 | 07-21-2021 |
$3.33 | $3.26 | $3.33 | $3.4 | $3.15 | 617,472 | 07-20-2021 |
$3.23 | $3.23 | $3.23 | $3.31 | $3.0701 | 875,819 | 07-19-2021 |
$3.37 | $3.45 | $3.37 | $3.53 | $3.25 | 380,164 | 07-16-2021 |
$3.36 | $3.37 | $3.36 | $3.37 | $3.15 | 601,134 | 07-15-2021 |
$3.36 | $3.37 | $3.36 | $3.61 | $3.2601 | 1,573,522 | 07-14-2021 |
$3.38 | $3.18 | $3.38 | $3.48 | $3.05 | 1,334,427 | 07-13-2021 |
$3.15 | $3.26 | $3.15 | $3.28 | $3.1 | 473,898 | 07-12-2021 |
$3.1873 | $3.06 | $3.1873 | $3.35 | $3.05 | 404,450 | 07-09-2021 |
$3.06 | $3.04 | $3.06 | $3.12 | $3 | 274,731 | 07-08-2021 |
$3.21 | $3.33 | $3.21 | $3.3865 | $3.12 | 369,141 | 07-07-2021 |
News, Short Squeeze, Breakout and More Instantly...
Intec Pharma Ltd. Company Name:
NTEC Stock Symbol:
NASDAQ Market:
Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural killer cells, dendritic cells, Th1 CD4, and CD8 T cells NEW YORK, March 25, 2024 (...
“Fully Engaging The Human Immune System To Cure Disease,” Featuring CEO, Jeffrey Meckler Registration now open at INDPMarch2024.TribePublic.com NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP), a clinical stage biotech...
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiat ing Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “...